Prognostic value of pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratio in diffuse large B-cell lymphoma: a single-center experience by G. Dagci, M. Guzel Mastanzade, M. Ozbalak, D. Ozluk, T. Tiryaki, I. Yonal Hindilerden, M. Yenerel, M. Nalcaci, S. Kalayoglu Besisik

Get full text

PB1899: DEVELOPMENT AND VALIDATION OF A PREDICTIVE SCORING SYSTEM FOR THE PROGNOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE RECEIVING FIRST-LINE IMATINIB by M. Bektaş, A. E. Eşkazan, T. O. Tiryaki, R. Mullai, T. Elverdi, A. Salihoğlu, M. Tiribelli, M. C. Ar, S. Öngören, Z. Başlar, M. Nalçaci, T. Soysal

Get full text

The frequency of calreticulin and mpl gene mutations in bcr-abl and jak2 unmutated chronic myeloproliferative neoplasms and its effect on the outcome by T. Tiryaki, A. DağLar Aday, M. Güzel Mastanzade, M. ÖZbalak, D. Özlük, F.Y. Onal Hindilerden, M. Yenerel, A. Yavuz, S. Kalayoğlu Beşışık, M. Nalçacı

Get full text

PB2074: IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA by O. Ilhan, G. Cengiz Seval, F. Avcu, B. Ferhanoglu, M. Ozcan, G. Cetin, E. Kurtoglu, H. Yilmaz, F. Atalay, E. Gulturk, M. Nalcaci, M. Beksac

Get full text

P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL by P. L. Zinzani, M. Özcan, K. Sapunarova, W. Jurczak, A. Hamed, K. Bouabdallah, G. Saydam, K. Geissler, Á. Szomor, M. Lazaroiu, A. Salar, A. Tempescul, M. Nalcaci, L. Gercheva, M. Egyed, P. Panayiotidis, L. Mongay Soler, A. Cao, C. Phelps, B. H Childs, M. J Matasar

Get full text